health
RAF inhibitor binding kinetics linked to tumour-selective suppression in models
A bioRxiv preprint reports that the RAF inhibitor ELV-3111, combined with a MEK inhibitor, suppressed MAPK signalling and produced tumour regressions in RAS- and BRAF-mutant models. The findings describe preclinical research, not patient outcomes.